CUA Educational Content

Evolving Treatment Paradigms in Advanced Urothelial Carcinoma

Featuring: Shilpa Gupta (Taussig Cancer Institute, Cleveland Clinic Foundation)


By participating in this program, participants can expect to:

  • review of latest evidence for treatment of advanced urothelial cancer
  • discuss the perspective on multidisciplinary approaches to optimize first line SOC treatments of chemotherapy and immunotherapy
  • gain insight on new approaches/research to further advance standard first-line treatment options for advanced urothelial carcinoma
Start Quiz for Credits

ACCREDITATION

This activity is an Accredited Self-Assessment Program (Section 3) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada, and approved by the Canadian Urological Association. You may claim a maximum of 1 hour of credit.

 

This program has received financial support from EMD Serono and Pfizer in the form of an educational grant.

The Canadian Urological Association (CUA) does not provide professional medical advice, diagnosis or treatment and cannot respond to requests for direct feedback, specific patient information or physician referrals. You should first always seek the advice of your urologist, physician and other qualified health provider with any questions regarding your medical condition. The contents of the CUA Website such as text, graphics, images, and other content are for informational purposes only. The content/information is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Never disregard professional medical advice or delay in seeking it because of something you have read on the CUA website.

For comments or information, email Corporate.office@cua.org

Privacy Policy